Carfilzomib Side Effects: What the Label and Studies Report

Where Carfilzomib Is Used and Who Supervises It

Carfilzomib is a prescription proteasome inhibitor administered intravenously by specialist clinicians in a hospital, oncology infusion unit or similar monitored setting. It is not a self-administered medicine, and it is not something handled outside supervised oncology care. Approved labelling covers treatment of relapsed or refractory multiple myeloma, alone and in specified combination regimens; any other use discussed in the literature, including solid tumour work, is investigational. Every question about whether the medicine applies to a particular situation, how it is given, or what a new symptom might mean belongs with the treating specialist team.

This page summarises what product labelling and published studies report about adverse events. It does not rank risks, does not estimate individual likelihood, and does not describe administration. This page is for educational purposes only and is not medical advice; consult a licensed physician or the prescribing oncology team about any symptom, medicine or treatment decision.

Mechanism in brief

Carfilzomib binds the proteasome and blocks protein degradation, which in myeloma cells overloads stress response pathways. Laboratory work on myeloma biology has examined how adaptive unfolded protein response signalling shapes sensitivity to this class of agent, as described in a 2025 mechanistic study of ZMYND8 and CEBPE transcription in multiple myeloma (PMID 40347515). A 2012 review of new proteasome inhibitors in myeloma placed carfilzomib among agents developed after bortezomib and discussed how their activity and tolerability profiles differed within the class (PMID 23065395).

Boxed Warning Status

United States prescribing information for carfilzomib does not carry a boxed warning. The absence of a boxed warning is a regulatory labelling fact and is not a statement about how serious the listed reactions can be: the same labelling describes fatal cardiac, renal, pulmonary and hepatic events under Warnings and Precautions. Those sections, summarised below, are the labelled safety content that the prescribing team works from.

Cardiovascular Adverse Events: What Studies Report

Cardiac toxicity is the most discussed safety theme for this agent. Labelling lists new or worsening cardiac failure, restrictive cardiomyopathy, myocardial ischemia and myocardial infarction, including fatal events, and notes that these have occurred early in treatment as well as later. Labelling also lists hypertension, including hypertensive crisis and hypertensive emergency, and venous thromboembolic events such as deep vein thrombosis and pulmonary embolism. Cardiac arrest and arrhythmias appear in the labelled adverse reaction tables.

Randomised trial data describe how these events present in combination regimens. In the IKEMA phase 3 trial of isatuximab, carfilzomib and dexamethasone compared with carfilzomib and dexamethasone in relapsed multiple myeloma, researchers reported that grade 3 or worse treatment-emergent adverse events and serious treatment-emergent adverse events occurred in a majority of patients in both arms, with cardiac failure among the events monitored in the carfilzomib-containing regimens (PMID 34097854). The LYNX study, which compared subcutaneous daratumumab plus carfilzomib and dexamethasone against carfilzomib and dexamethasone in patients with relapsed or refractory myeloma previously treated with daratumumab, also reported treatment-emergent adverse events in both arms as part of its safety analysis (PMID 41041907).

Beyond trials, an analysis of real-world pharmacovigilance reporting examined anticancer drugs associated with atrial fibrillation and reported disproportionality signals across several drug classes used in haematological malignancy (PMID 35498039). Spontaneous reporting analyses of that kind describe reporting patterns rather than incidence, and the authors of such work generally note that signals require clinical interpretation (PMID 35498039).

Renal Adverse Events: What Studies Report

Labelling lists acute renal failure, including fatal cases, with reports more common in patients with advanced relapsed and refractory disease, along with decreased creatinine clearance and tumour lysis syndrome. A dedicated retrospective analysis of 114 patients with multiple myeloma reported that carfilzomib-associated renal toxicity was common and that the researchers could not predict which patients would develop it from the characteristics examined (PMID 33149167). That study framed renal monitoring as a routine part of care during treatment rather than an occasional concern (PMID 33149167).

Labelling also lists thrombotic microangiopathy, including thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome, which can present with renal impairment together with thrombocytopenia and haemolysis. A practical review of relapsed myeloma management discussed monitoring and supportive care considerations for patients receiving contemporary regimens, including attention to organ toxicity during treatment (PMID 27986429).

Pulmonary Adverse Events: What Studies Report

Labelled pulmonary warnings include acute respiratory distress syndrome, acute respiratory failure, acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease, pulmonary hypertension and dyspnoea. Dyspnoea and cough appear among the frequently reported adverse reactions in the labelled trial tables.

The pulmonary hypertension entry sits beside an unexpected preclinical finding: a 2016 cardiovascular research study reported that carfilzomib reversed pulmonary arterial hypertension in experimental models (PMID 26952044). Preclinical model results of that kind do not describe what happens in patients treated for myeloma, and the labelled warning about pulmonary hypertension stands independently of that experimental work (PMID 26952044).

Haematologic and Infection-Related Adverse Events: What Studies Report

Labelling lists thrombocytopenia, with platelet nadirs during the dosing cycle, anaemia, neutropenia, lymphopenia and haemorrhage, including gastrointestinal, pulmonary and intracranial bleeding, some fatal. Infections, including pneumonia, sepsis, herpes zoster reactivation and hepatitis B virus reactivation, appear in the labelled warnings and adverse reaction sections. Progressive multifocal leukoencephalopathy, a rare viral brain infection, is listed as well.

Randomised trial safety reporting in myeloma combinations reflects the same themes: the IKEMA trial reported haematologic toxicity and infection among the treatment-emergent adverse events tracked in both the isatuximab-containing and control carfilzomib arms (PMID 34097854), and the LYNX study reported safety outcomes for carfilzomib and dexamethasone with and without subcutaneous daratumumab in a previously daratumumab-treated population (PMID 41041907).

Hepatic, Neurologic and Infusion-Related Events: What Studies Report

Labelling describes hepatic toxicity and hepatic failure, including fatal cases, with elevations in transaminases and bilirubin. Posterior reversible encephalopathy syndrome, presenting with headache, seizure, visual disturbance or altered consciousness, is listed as a rare neurological warning. Infusion-related reactions, which labelling describes as occurring during or shortly after administration with features such as fever, chills, rigors, flushing, dyspnoea and hypotension, are also listed, as is tumour lysis syndrome in patients with high tumour burden.

Peripheral neuropathy is a recurring point of comparison within the proteasome inhibitor class. Reviews of therapy in Waldenstrom macroglobulinaemia have discussed how proteasome inhibitors are selected partly on the basis of neuropathy profiles when planning treatment (PMID 30190021), and a guideline-oriented review of Waldenstrom macroglobulinaemia therapy covered the same class considerations within treatment algorithms (PMID 27825466). A broader review of drug therapy for lymphomas described where targeted agents, including proteasome inhibition, sit among systemic options (PMID 28273193).

Commonly Reported Adverse Reactions in Labelling

Prescribing information groups the most common adverse reactions as those reported in at least twenty percent of patients in the trials summarised in the label. The grouping below reflects labelled categories rather than a ranking of severity.

Labelled frequency tables are derived from trial populations with relapsed or refractory multiple myeloma who were receiving combination therapy and supportive medicines, so the reported rates describe those study populations rather than any individual.

Investigational Settings Reported in the Literature

Work outside the approved indication is investigational. A 2025 report described continuous hepatic artery infusion as a route being explored for proteasome inhibition in solid tumours, a delivery approach that sits entirely within research settings (PMID 41196694). Adverse event profiles observed in such investigational contexts are not interchangeable with the labelled safety profile for approved myeloma regimens (PMID 41196694).

How Safety Information Is Generated and Its Limits

• Randomised trials report adverse events in selected populations with defined organ function criteria, as in the IKEMA phase 3 comparison in relapsed multiple myeloma (PMID 34097854).
• Retrospective cohort analyses capture routine care experience, as in the analysis of renal toxicity across 114 patients with multiple myeloma (PMID 33149167).
• Pharmacovigilance databases describe reporting patterns and generate signals rather than incidence, as in the real-world analysis of anticancer drugs associated with atrial fibrillation (PMID 35498039).
• Narrative reviews summarise practice considerations, as in a review of practical management in relapsed multiple myeloma (PMID 27986429).

Across these sources, the reported event rates depend on the population studied, the companion drugs used, the duration of follow-up and how events were collected. Comparisons between a trial arm and a registry signal are therefore not direct.

Where Symptom Questions Belong

Chest pain, breathlessness, swelling, reduced urine output, bleeding, fever, confusion, visual change or reaction symptoms during or after an infusion are all events that labelling associates with this medicine, and recognising them is the job of the clinical team providing treatment. Anyone receiving or considering carfilzomib should talk to the prescriber or the treating oncology service about symptoms, monitoring and treatment choices. Nothing on this page substitutes for that conversation.

References

• Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial (Lancet, 2021)
• Subcutaneous daratumumab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma: LYNX study (Leukemia & Lymphoma, 2025)
• Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients (Blood Cancer Journal, 2020)
• Anti-cancer Drugs Associated Atrial Fibrillation: An Analysis of Real-World Pharmacovigilance Data (Frontiers in Cardiovascular Medicine, 2022)
• Carfilzomib reverses pulmonary arterial hypertension (Cardiovascular Research, 2016)
• New proteasome inhibitors in myeloma (Current Hematologic Malignancy Reports, 2012)
• Practical Considerations in Managing Relapsed Multiple Myeloma (Clinical Lymphoma, Myeloma & Leukemia, 2017)
• Proteasome Inhibitors in Waldenstrom Macroglobulinemia (Hematology/Oncology Clinics of North America, 2018)
• Current therapy guidelines for Waldenstrom's macroglobulinaemia (Best Practice & Research Clinical Haematology, 2016)
• Drug therapy of lymphomas (Magyar Onkologia, 2017)
• ZMYND8 Reads H3K36me2 to Activate CEBPE Transcription and Suppress Multiple Myeloma Progression through the Inhibition of Adaptive UPR Pathways (Advanced Science, 2025)
• A rebrand for proteasome inhibition in solid tumors via continuous hepatic artery infusion (JCI Insight, 2025)